Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (2)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2019 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to raise capital for the continued development of projects and to strengthen the company’s shareholder base.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Joel Magnusson.

Related

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

 Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

 Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025